Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

In Partnership With:

Partner | Cancer Centers | <b>Wake Forest Comprehensive Cancer Center</b>

Bayard L. Powell, MD, Section Chief of Hematology and Oncology and Director of Leukemia Services at

Wake Forest University Baptist Medical Center, discusses using the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).




The results of the recent phase study promising. The combination has been effective, with 54% of patients showing a response and no increased toxicity occurring from the addition of CPI-613. The combination was particularly beneficial for patients over 60 and patients with poor risk cytogenetics, says